BACK TO TOP

90
Newswise imageThe U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, this time for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy. Today's approval includes treatment of diffuse large B-cell lymphoma (DLBCL) - the most common form of non-Hodgkin's lymphoma - as well as high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.


Advertise With Us!

Dietary Supplement & Health Search Engine

Dietary Supplement Reviews from users worldwide. Get up to date dietary supplement information from name brand dietary supplement makers at DietarySupplement.com








Featured Supplements

Advertise With Us!